Cynata
An Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on a proprietary therapeutic stem cell platform technology.
Launch date
Employees
Market cap
AUD34.3m
Enterprise valuation
AUD28m (Public information from Sep 2024)
Share price
AUD0.19 CYP.AX
Melbourne Victoria (HQ)
Financials
Estimates*
| AUD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 7.0m | - | - | - | 2.3m | <1m | 7.2m |
| % growth | 250 % | - | - | - | - | (61 %) | 700 % |
| EBITDA | (10.2m) | (8.8m) | (13.6m) | (16.3m) | (9.3m) | (8.2m) | (4.4m) |
| % EBITDA margin | (146 %) | - | - | - | (402 %) | (911 %) | (61 %) |
| Profit | (3.6m) | (7.7m) | (5.4m) | (14.3m) | (9.4m) | (8.3m) | (4.6m) |
| % profit margin | (52 %) | - | - | - | (406 %) | (922 %) | (64 %) |
| EV / revenue | 8.3x | - | - | - | 22.9x | 12.7x | 2.6x |
| EV / EBITDA | -5.7x | - | - | -1.4x | -5.7x | -1.4x | -4.3x |
| R&D budget | 5.9m | 3.8m | 8.8m | 12.4m | - | - | - |
| R&D % of revenue | 85 % | - | - | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | $2.9m | Post IPO Equity | |
$6.0m | Post IPO Equity | ||
AUD5.2m | Post IPO Equity | ||
AUD50.0k | Grant | ||
AUD15.0m | Private Placement VC | ||
AUD1.4m | Grant | ||
* | AUD1.0m | Grant | |
| Total Funding | AUD17.4m | ||
Related Content
Recent News about Cynata
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.